trending Market Intelligence /marketintelligence/en/news-insights/trending/Tg-TvBM6KiZ9DqWkjMZUaA2 content esgSubNav
In This List

Nuvectra applies for US FDA approval of sacral nerve stimulation system

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Nuvectra applies for US FDA approval of sacral nerve stimulation system

Nuvectra Corp. submitted a pre-market approval application to the U.S. FDA for Virtis, its sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder.

The pre-market approval application, along with a submission to CE Mark authorities, positions the company to release the system in the European market by the end of 2017 and to begin commercialization efforts in the U.S. sometime in 2018, pending timely regulatory approval from each authority.